Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for olaparib (AstraZeneca/Merck's Lynparza) as a first-line maintenance treatment in combination with bevacizumab (Genentech's Avastin) for certain patients with advanced, high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.